Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Emphysema phenotypes and lung cancer risk.

González J, Henschke CI, Yankelevitz DF, Seijo LM, Reeves AP, Yip R, Xie Y, Chung M, Sánchez-Salcedo P, Alcaide AB, Campo A, Bertó J, Del Mar Ocón M, Pueyo J, Bastarrika G, de-Torres JP, Zulueta JJ.

PLoS One. 2019 Jul 25;14(7):e0219187. doi: 10.1371/journal.pone.0219187. eCollection 2019.

2.

Telomere length, COPD and emphysema as risk factors for lung cancer.

de-Torres JP, Sanchez-Salcedo P, Bastarrika G, Alcaide AB, Pío R, Pajares MJ, Campo A, Berto J, Montuenga L, Del Mar Ocon M, Monente C, Celli BR, Zulueta JJ.

Eur Respir J. 2017 Jan 3;49(1). pii: 1601521. doi: 10.1183/13993003.01521-2016. Print 2017 Jan. No abstract available.

3.

Clinical Features of Smokers With Radiological Emphysema But Without Airway Limitation.

Alcaide AB, Sanchez-Salcedo P, Bastarrika G, Campo A, Berto J, Ocon MD, Fernandez-Montero A, Celli BR, Zulueta JJ, de-Torres JP.

Chest. 2017 Feb;151(2):358-365. doi: 10.1016/j.chest.2016.10.044. Epub 2016 Nov 3.

PMID:
27818328
4.

Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT.

Garcia-Velloso MJ, Bastarrika G, de-Torres JP, Lozano MD, Sanchez-Salcedo P, Sancho L, Nuñez-Cordoba JM, Campo A, Alcaide AB, Torre W, Richter JA, Zulueta JJ.

Lung Cancer. 2016 Jul;97:81-6. doi: 10.1016/j.lungcan.2016.04.025. Epub 2016 May 2.

PMID:
27237032
5.

The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development.

Sanchez-Salcedo P, de-Torres JP, Martinez-Urbistondo D, Gonzalez-Gutierrez J, Berto J, Campo A, Alcaide AB, Zulueta JJ.

Lung Cancer. 2016 Jul;97:28-34. doi: 10.1016/j.lungcan.2016.04.010. Epub 2016 Apr 16.

PMID:
27237024
6.

Lung cancer screening in patients with chronic obstructive pulmonary disease.

Gonzalez J, Marín M, Sánchez-Salcedo P, Zulueta JJ.

Ann Transl Med. 2016 Apr;4(8):160. doi: 10.21037/atm.2016.03.57. Review.

7.

Is COPD a Progressive Disease? A Long Term Bode Cohort Observation.

de-Torres JP, Marín JM, Pinto-Plata V, Divo M, Sanchez-Salcedo P, Zagaceta J, Zulueta JJ, Berto J, Cabrera C, Celli BR, Casanova C.

PLoS One. 2016 Apr 21;11(4):e0151856. doi: 10.1371/journal.pone.0151856. eCollection 2016.

8.

Lung cancer in chronic obstructive pulmonary disease patients, it is not just the cigarette smoke.

Sanchez-Salcedo P, Zulueta JJ.

Curr Opin Pulm Med. 2016 Jul;22(4):344-9. doi: 10.1097/MCP.0000000000000283. Review.

PMID:
27077725
9.

COPD comorbidities network.

Divo MJ, Casanova C, Marin JM, Pinto-Plata VM, de-Torres JP, Zulueta JJ, Cabrera C, Zagaceta J, Sanchez-Salcedo P, Berto J, Davila RB, Alcaide AB, Cote C, Celli BR; BODE Collaborative Group.

Eur Respir J. 2015 Sep;46(3):640-50. doi: 10.1183/09031936.00171614. Epub 2015 Jul 9.

10.

Immunomodulating effects of glatiramer acetate and its potential role in pulmonary tuberculosis reactivation.

Sánchez-Salcedo P, de-Torres JP.

Arch Bronconeumol. 2015 Dec;51(12):656-7. doi: 10.1016/j.arbres.2015.03.016. Epub 2015 Jun 3. English, Spanish. No abstract available.

11.

BODE Index: A Good Quality of Life Marker in Chronic Obstructive Pulmonary Disease Patients.

Sanchez-Salcedo P, de Torres JP.

Arch Bronconeumol. 2015 Jul;51(7):311-2. doi: 10.1016/j.arbres.2015.03.003. Epub 2015 Apr 21. English, Spanish. No abstract available.

12.

Improving selection criteria for lung cancer screening. The potential role of emphysema.

Sanchez-Salcedo P, Wilson DO, de-Torres JP, Weissfeld JL, Berto J, Campo A, Alcaide AB, Pueyo J, Bastarrika G, Seijo LM, Pajares MJ, Pio R, Montuenga LM, Zulueta JJ.

Am J Respir Crit Care Med. 2015 Apr 15;191(8):924-31. doi: 10.1164/rccm.201410-1848OC.

13.

Lung cancer screening: fourteen year experience of the Pamplona early detection program (P-IELCAP).

Sanchez-Salcedo P, Berto J, de-Torres JP, Campo A, Alcaide AB, Bastarrika G, Pueyo JC, Villanueva A, Echeveste JI, Lozano MD, García-Velloso MJ, Seijo LM, García J, Torre W, Pajares MJ, Pío R, Montuenga LM, Zulueta JJ.

Arch Bronconeumol. 2015 Apr;51(4):169-76. doi: 10.1016/j.arbres.2014.09.019. Epub 2015 Jan 29. English, Spanish.

14.

Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score.

de-Torres JP, Wilson DO, Sanchez-Salcedo P, Weissfeld JL, Berto J, Campo A, Alcaide AB, García-Granero M, Celli BR, Zulueta JJ.

Am J Respir Crit Care Med. 2015 Feb 1;191(3):285-91. doi: 10.1164/rccm.201407-1210OC.

15.

Comorbidity Distribution, Clinical Expression and Survival in COPD Patients with Different Body Mass Index.

Divo MJ, Cabrera C, Casanova C, Marin JM, Pinto-Plata VM, de-Torres JP, Zulueta J, Zagaceta J, Sanchez-Salcedo P, Berto J, Cote C, Celli BR.

Chronic Obstr Pulm Dis. 2014 Sep 25;1(2):229-238. doi: 10.15326/jcopdf.1.2.2014.0117.

16.

Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE.

de Torres JP, Casanova C, Marín JM, Pinto-Plata V, Divo M, Zulueta JJ, Berto J, Zagaceta J, Sanchez-Salcedo P, Cabrera C, Carrizo S, Cote C, Celli BR.

Thorax. 2014 Sep;69(9):799-804. doi: 10.1136/thoraxjnl-2014-205770. Epub 2014 Jun 26.

PMID:
24969641
17.

Disease progression in young patients with COPD: rethinking the Fletcher and Peto model.

Sanchez-Salcedo P, Divo M, Casanova C, Pinto-Plata V, de-Torres JP, Cote C, Cabrera C, Zagaceta J, Rodriguez-Roisin R, Zulueta JJ, Marin JM, Celli B.

Eur Respir J. 2014 Aug;44(2):324-31. doi: 10.1183/09031936.00208613. Epub 2014 Apr 2.

Supplemental Content

Loading ...
Support Center